Last updated on March 2016

A Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS


Brief description of study

The primary objective is to assess the pharmacokinetics (PK) of gabapentin following the single-dose administration of HORIZANT (Gabapentin Enacarbil) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe Primary Restless Legs Syndrome (RLS).

Clinical Study Identifier: NCT02633657

Find a site near you

Start Over

Xenoport Investigational Site

Redwood City, CA United States
  Connect »

Xenoport Investigational Site

San Diego, CA United States
  Connect »

Xenoport Investigational Site

Nashville, TN United States
  Connect »